Zepbound during IVF: what the evidence actually says

What did @clareelisabeth actually say?

In week two of tirzepatide (Zepbound), @clareelisabeth described dramatic appetite suppression in the first few days post-injection, with hunger returning toward the end of the week. She reported "pins and needles" itching in her legs at night, dry skin she attributed to dehydration, and two days of severe post-injection fatigue she called being "dead to the world." She also mentioned she's coming off prednisone and doing IVF simultaneously, and that she wants to escalate her dose within four to five months.

She was transparent about telling her doctor about the itching and was clear she understood it wasn't anaphylaxis. That level of self-awareness matters, especially given she's juggling active fertility treatment with a GLP-1 medication.

Does the science back this up?

The appetite suppression pattern she described, strong in the first few days post-injection then fading, is real and well-documented. The fatigue claim has more nuance. The itching symptoms are less clearly tied to dehydration and deserve more scrutiny.

On appetite: tirzepatide works on both GIP and GLP-1 receptors, and pharmacokinetically, plasma concentrations peak roughly 8-72 hours post-injection for the subcutaneous formulation. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) confirmed significant reductions in appetite and caloric intake across all dose arms. Her observation that food noise faded fast, then returned by day six or seven, tracks with the drug's half-life of approximately five days and the trough before the next dose.

On fatigue: post-injection fatigue is reported anecdotally but is not a prominently listed adverse event in the prescribing information. Some researchers hypothesize it relates to rapid shifts in glucose metabolism or caloric restriction. It is not well-characterized in controlled trials.

On the itching: this is where it gets complicated. She attributes it to dehydration causing dry skin, but GLP-1-class drugs are associated with hypersensitivity reactions including pruritus. The FDA label for Zepbound lists hypersensitivity as a warning. Pruritus specifically was reported in trials. This is not the same as dry skin from drinking less water.

What did they get wrong (or right)?

She got the appetite suppression pattern right. The GI slowdown description, mild constipation without needing intervention, also aligns with what the clinical data shows at the 2.5 mg starting dose.

Where she went wrong: attributing the nocturnal leg itching to dehydration is an oversimplification that could be misleading to viewers. Pruritus is a documented side effect that in some cases signals a hypersensitivity response, not just dry skin. Reaching for Zyrtec and Benadryl and calling it handled is understandable, but framing it primarily as a hydration issue downplays what might actually be happening pharmacologically.

She also mentions wanting to escalate to the next dose quickly, within four to five months of starting. The prescribing information recommends at least four weeks at each dose level before escalating, and titration decisions belong with a physician, not a TikTok timeline. That comment, while casual, could influence viewers to push their own doctors faster than is appropriate.

• Appetite suppression pattern: accurate and backed by trial data
• GI slowing without severe constipation: plausible at the starting dose
• Dry skin equals dehydration: too simple, ignores documented pruritus risk
• Dose escalation framing: potentially sets unrealistic expectations for viewers

What should you actually know?

If you experience nocturnal itching or "pins and needles" on a GLP-1 medication, do not assume it is just dry skin. Pruritus and hypersensitivity reactions are listed in the Zepbound prescribing information. Tell your prescriber specifically and promptly, not just as an aside. Antihistamines may mask symptoms that warrant a closer look.

Second, the concurrent use of Zepbound during IVF is not a trivial detail. Tirzepatide is rated FDA Pregnancy Category not established, and animal studies showed fetal harm at high doses. Most reproductive endocrinologists would not recommend active GLP-1 use during an IVF cycle, particularly during stimulation or transfer phases. This video does not address that tension at all, and viewers doing their own IVF research should not treat this as a template.

Third, fatigue after injection is worth tracking and worth reporting. It is not just a lifestyle inconvenience to power through with a gym session. If it is severe and recurring, that is clinical information your prescriber needs.